Drugs With Low Clinical Benefit Show Higher Direct-to-Consum

WEDNESDAY Feb. 15, 2023 (HealthDay News) -- Among the top-selling U.S. drugs, those with lower added clinical benefit ratings and higher total drug sales have higher manufacturer spending on direct-to-consumer

Related Keywords

United States , American , Michaelj Distefano , , Johns Hopkins University In Baltimore , National Sales Perspectives , Journal Of The American Medical Association , Healthday News , American Medical , Johns Hopkins University , Sales Perspectives , Physicians Briefing ,